Myeloid Malignancies Mutation Panel by Next Generation Sequencing

2011117
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive
COMPONENT DESCRIPTION TEST TYPE INFECTIOUS UNIT OF MEASURE NUMERIC MAP LOINC
2011118
Myeloid Malignancy Proposed Diagnosis
PROMPT
N
2011119
Myeloid Malignancies Panel Specimen
PROMPT
N
31208-2
2011120
Myeloid Malignancies Panel Interp
Resultable
N
35474-6
2011121
EER Myeloid Malignancies Panel by NGS
Resultable
N
11526-1

For questions regarding the Interface Map, please contact interface.support@aruplab.com.


Download to Excel

Icon

Additional Technical Information
Ordering Recommendation

Assess for single gene mutations, including substitutions and smaller insertions and deletions that may have prognostic and/or therapeutic significance in AML, myelodysplastic syndromes, myeloproliferative neoplasms, or MDS/MPN overlap disorders such as chronic myelomonocytic leukemia.

Mnemonic
MYE NGS
Methodology

Massively Parallel Sequencing

Performed

Varies

Reported

12-14 days

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect

Lavender (K2EDTA) OR Bone Marrow (EDTA).

Specimen Preparation

Do not freeze. Transport 5 mL whole blood. (Min: 1 mL) OR Transport 3 mL bone marrow. (Min: 1 mL)Separate specimens must be submitted when multiple tests are ordered.

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Serum, plasma or tissue. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.

Remarks
Stability

Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

The diagnosis under consideration is required information to order this test. Genes tested: ANKRD26, ASXL1, ASXL2, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CEBPA, CSF3R, CUX1*, DDX41, DNMT1*, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HNRNPK, IDH1, IDH2, IL7R, JAK1, JAK2, JAK3, KDM6A*, KIT, KMT2A, KRAS, LUC7L2, MPL, NOTCH1, NPM1*, NRAS, NSD1, PHF6, PIGA, PRPF40B, PRPF8, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B*, SUZ12*, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2

* - One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/20/2019
X
N/A
CPT Codes

81455

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2011118 Myeloid Malignancy Proposed Diagnosis
2011119 Myeloid Malignancies Panel Specimen 31208-2
2011120 Myeloid Malignancies Panel Interp 35474-6
2011121 EER Myeloid Malignancies Panel by NGS 11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Acute myeloid leukemia, AML
  • Atypical chronic myelogenous leukemia, aCML
  • Chronic eosinophilic leukemia not otherwise specified
  • Chronic myelogenous leukemia, BCR-ABL1 positive, CML
  • Chronic myelomonocytic leukemia, CMML
  • Chronic neutrophilic leukemia, CNL
  • Eosinophilia
  • Juvenile myelomonocytic leukemia, JMML
  • Mastocytosis
  • Myelodysplastic syndrome with isolated del(5q)
  • Myelodysplastic syndromes, MDS
  • Myelodysplastic/Myeloproliferative neoplasm
  • Myeloproliferative neoplasm, essential thrombocythemia, MPN-ET
  • Myeloproliferative neoplasm, MDS/MPN
  • Myeloproliferative neoplasm, polycythemia vera, MPN-PV
  • Myeloproliferative neoplasm, primary myelofibrosis, MPN-PMF
  • Refractory anemia with excess blasts, RAEB
  • Refractory anemia with ring sideroblasts associated with marked thrombocytosis, RARS-T
  • Refractory anemia with ring sideroblasts, RARS
  • Refractory cytopenia with multilineage dysplasia, RCMD
  • Refractory cytopenia with unilineage dsysplasia, RCUD
Myeloid Malignancies Mutation Panel by Next Generation Sequencing